Physician profile
Scott D Lippe
NPI 1992766844
$3,305.09
in general payments reported to CMS, 2019-2025
30 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.74 · 2020: $351 · 2021: $444 · 2022: $915 · 2023: $419 · 2024: $610 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $595.59 | 2020-2023 | Trulance, Xifaxan |
| Celgene Corporation | $577.18 | 2021-2024 | Zeposia |
| Abbvie INC. | $483.73 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $382.02 | 2020-2025 | Entyvio |
| Medtronic, INC. | $367.47 | 2024-2025 | Minimed 780g |
| Janssen Biotech, INC. | $181.82 | 2021-2025 | Tremfya, Stelara, Simponi |
| Evoke Pharma, INC. | $99.27 | 2020-2025 | |
| Redhill Biopharma INC. | $75.00 | 2020-2021 | |
| Pfizer INC. | $72.38 | 2021-2025 | |
| Qol Medical, LLC | $67.40 | 2021-2023 | Sucraid |
| Gilead Sciences, INC. | $59.62 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $40.00 | 2020-2021 | |
| Braintree Laboratories, INC. | $25.22 | 2025 | Suflave, Sutab |
| Incyte Corporation | $24.77 | 2025 | Jakafi |
| Nestle Healthcare Nutrition INC. | $22.65 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.36 | 2024 | Dificid, Lagevrio |
| Regeneron Healthcare Solutions, INC. | $19.97 | 2025 | Dupixent |
| Lilly USA, LLC | $19.44 | 2025 | Zepbound |
| Novo Nordisk INC | $19.29 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $18.24 | 2025 | |
| Amgen INC. | $17.97 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.30 | 2025 | Iqirvo |
| Echosens North America, INC. | $15.00 | 2020 | |
| Allergan, INC. | $14.69 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.38 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.87 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.27 | 2023 | Rebyota |
| Endo Pharmaceuticals INC. | $12.87 | 2019 | |
| Eisai INC. | $12.83 | 2021 | |
| Phathom Pharmaceuticals, INC. | $1.49 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.